Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 4, 2014, Pages 479-496

  Pinazo, Maria Jesús ^a   Thomas, M Carmen ^b   Bua, Jacqueline ^c,d   Perrone, Alina ^c,d   Schijman, Alejandro Gabriel ^e   Viotti, Rodolfo Jorge ^f   Ramsey, Janine M ^g   Ribeiro, Isabela ^h   Sosa Estani, Sergio ^c,d   López, Manuel Carlos ^b   Gascon, Joaquim ^a  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c Administracion Nacional de Laboratorios E Institutos de Salud Dr Carlos G Malbran   (Argentina)

^d Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^e INSTITUTO DE INVESTIGACIONES EN INGENIERÍA GENÉTICA Y BIOLOGÍA MOLECULAR   (Argentina)

^f Hospital Eva Peron   (Argentina)

^g INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^h Drugs for Neglected Diseases Initiative   (Switzerland)

Author keywords

biological marker; biomarker; Chagas disease; cure marker; humoral and cellular immune response; PCR; treatment; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; BIOLOGICAL MARKER; CELL MARKER; GAMMA INTERFERON; MUSCARINIC M2 RECEPTOR; NIFURTIMOX; PADGEM PROTEIN; PARASITE ANTIGEN; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ANTITRYPANOSOMAL AGENT;

ANTIGEN DETECTION; CHAGAS DISEASE; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; NUCLEIC ACID AMPLIFICATION; PATIENT IDENTIFICATION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADOLESCENT; ADULT; AGED; BLOOD; CELLULAR IMMUNITY; CHILD; DISEASE COURSE; HUMORAL IMMUNITY; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHAGAS DISEASE; CHILD; DISEASE PROGRESSION; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MIDDLE AGED; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS;

EID: 84896357912     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.899150     Document Type: Review

References (91)

1. World Health Organization (WHO). Chagas disease (American trypanosomiasis). 2013;2013(340)
2. Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010;115(1-2):22-7
3. Schmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 2010; 115(1-2):14-21
4. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis 2013;13(4):342-8
5. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. Jama 2007;298(18):2171-81
6. World Health Organization (WHO). Control of Chagas' disease. 2002;1-109
7. Viotti R, De Noya BA, Araujo-Jorge T, et al. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother 2013;58(2): 635-9
8. Schijman AG, Vigliano CA, Viotti RJ, et al. Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic chagas heart disease. Am J Trop Med Hyg 2004;70(2):210-20
9. Kierszenbaum F. Where do we stand on the autoimmunity hypothesis of Chagas disease? Trends Parasitol 2005;21(11):513-16
10. Rodriques Coura J, De Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002;97(1):3-24
11. Marin-Neto JA, Rassi A Jr, Morillo CA, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008;156(1):37-43
12. Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009;7(2): 157-63
13. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006;144(10):724-34
14. Fabbro DL, Streiger ML, Arias ED, et al. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007;40(1):1-10
15. Laucella SA, Segura EL, Riarte A, Sosa ES. Soluble platelet selectin (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease. Clin Exp Immunol 1999;118(3):423-7
16. Girones N, Rodriguez CI, Basso B, et al. Antibodies to an epitope from the Cha human autoantigen are markers of Chagas' disease. Clin Diagn Lab Immunol 2001; 8(6):1039-43
17. Cutrullis RA, Moscatelli GF, Moroni S, et al. Benzonidazole therapy modulates interferon-gamma and M2 muscarinic receptor autoantibody responses in Trypanosoma cruzi-infected children. PLoS One 2011;6(10):e27133
18. Galvao LM, Nunes RM, Cancado JR, et al. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg 1993;87(2):220-3
19. Krautz GM, Galvao LM, Cancado JR, et al. Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease. J Clin Microbiol 1995;33(8):2086-90
20. Levy AM, Boainain E, Kloetzel JK. In situ indirect fluorescent antibody: a new specific test to detect ongoing chagasic infections. J Clin Lab Anal 1996;10(2):98-103
21. Cancado Jr. Criteria of Chagas disease cure. Mem Inst Oswaldo Cruz 1999;94 Suppl 1:331-5
22. Cancado Jr. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 2002;44(1):29-37
23. De Andrade AL, Zicker F, De Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348(9039):1407-13
24. Andrade AL, Martelli CM, Oliveira RM, et al. Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am J Trop Med Hyg 2004;71(5):594-7
25. Sosa Estani S, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998;59(4):526-9
26. Moretti E, Cervetta L, Basso B, et al. [Chronic Chagas' disease: effects of treatment nn the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens]. Bol Chil Parasitol 1998; 53(1-2):3-9
27. Meira WS, Galvao LM, Gontijo ED, et al. Use of the Trypanosoma cruzi recombinant complement regulatory protein to evaluate therapeutic efficacy following treatment of chronic chagasic patients. J Clin Microbiol 2004;42(2):707-12
28. Da Silveira JF, Umezawa ES, Luquetti AO. Chagas disease: recombinant Trypanosoma cruzi antigens for serological diagnosis. Trends Parasitol 2001;17(6):286-91
29. Ibanez CF, Affranchino JL, Macina RA, et al. Multiple Trypanosoma cruzi antigens containing tandemly repeated amino acid sequence motifs. Mol Biochem Parasitol 1988;30(1):27-33
30. Vergara U, Lorca M, Veloso C, et al. Assay for detection of Trypanosoma cruzi antibodies in human sera based on reaction with synthetic peptides. J Clin Microbiol 1991;29(9):2034-7
31. Sanchez Negrette O, Sanchez Valdez FJ, Lacunza CD, et al. Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease. Clin Vaccine Immunol 2008;15(2):297-302
32. Cooley G, Etheridge RD, Boehlke C, et al. High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis 2008;2(10): e316
33. Viotti R, Vigliano C, Alvarez MG, et al. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl Trop Dis 2011;5(9):e1314
34. Fernandez-Villegas A, Pinazo MJ, Maranon C, et al. Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers. BMC Infect Dis 2011;11:206
35. Fabbro DL, Olivera V, Bizai ML, et al. Humoral immune response against P2beta from Trypanosoma cruzi in persons with chronic Chagas disease: its relationship with treatment against parasites and myocardial damage. Am J Trop Med Hyg 2011;84(4): 575-80
36. Vitelli-Avelar DM, Sathler-Avelar R, Teixeira-Carvalho A, et al. Strategy to assess the overall cytokine profile of circulating leukocytes and its association with distinct clinical forms of human Chagas disease. Scand J Immunol 2008;68(5):516-25
37. Sathler-Avelar R, Vitelli-Avelar DM, Eloi-Santos SM, et al. Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with Trypanosoma cruzi antigens. BMC Infect Dis 2012;12:123
38. Guedes PM, Gutierrez FR, Silva GK, et al. Deficient regulatory T cell activity and low frequency of IL-17-producing T cells correlate with the extent of cardiomyopathy in human Chagas' disease. PLoS Negl Trop Dis 2012;6(4):e1630
39. Dutra WO, Da Luz ZM, Cancado JR, et al. Influence of parasite presence on the immunologic profile of peripheral blood mononuclear cells from chagasic patients after specific drug therapy. Parasite Immunol 1996;18(11):579-85
40. Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, et al. Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. Microbes Infect 2008;10(2):103-13
41. Laucella SA, Mazliah DP, Bertocchi G, et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 2009;49(11): 1675-84
42. Cooley G, Etheridge RD, Boehlke C, et al. High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis 2008;2(10): e316
43. Arguello RJ, Albareda MC, Alvarez MG, et al. Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease. PLoS ONE 2012;7(5): e35966
44. Lima-Costa MF, Cesar CC, Peixoto SV, Ribeiro AL. Plasma B-type natriuretic peptide as a predictor of mortality in community-dwelling older adults with Chagas disease: 10-year follow-up of the Bambui Cohort Study of Aging. Am J Epidemiol 2010;172(2):190-6
45. Moreira Mda C, Heringer-Walther S, Wessel N, et al. Prognostic value of natriuretic peptides in Chagas' disease: a 3-year follow-up investigation. Cardiology 2008;110(4):217-25
46. Puyo AM, Scaglione J, Auger S, et al. Atrial natriuretic factor as marker of myocardial compromise in Chagas' disease. Regul Pept 2002;105(2):139-43
47. Puyo AM, Scaglione J, Auger S, et al. Natriuretic peptides as prognostic and diagnostic markers in Chagas' disease. Regul Pept 2005;128(3):203-10
48. Garcia-Alvarez A, Sitges M, Pinazo MJ, et al. Chagas cardiomyopathy: the potential of diastolic dysfunction and brain natriuretic peptide in the early identification of cardiac damage. PLoS Neg Trop Dis 2010;4(9):pii: e826
49. Heringer-Walther S, Moreira MC, Wessel N, et al. Brain natriuretic peptide predicts survival in Chagas' disease more effectively than atrial natriuretic peptide. Heart 2005;91(3):385-7
50. Ribeiro AL, Reis AM, Teixeira MM, Rocha MO. Brain natriuretic peptide in Chagas' disease: further insights. Lancet 2003;362(9380):333
51. Melo RB, Parente GB, Victor EG. Measurement of human brain natriuretic peptide in patients with Chagas' disease. Arq Bras Cardiol 2005;84(2):137-40
52. Barbosa MM, Nunes Mdo C, Ribeiro AL, et al. N-terminal proBNP levels in patients with Chagas disease: a marker of systolic and diastolic dysfunction of the left ventricle. Eur J Echocardiogr 2007;8(3): 204-12
53. Mady C, Fernandes F, Arteaga E, et al. Serum NT pro-BNP: relation to systolic and diastolic function in cardiomyopathies and pericardiopathies. Arq Bras Cardiol 2008;91(1):46-54
54. Fernandes F, Dantas S, Ianni BM, et al. Leptin levels in different forms of Chagas' disease. Braz J Med Biol Res 2007;40(12): 1631-6
55. Ribeiro AL, Dos Reis AM, Barros MV, et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. Lancet 2002;360(9331):461-2
56. Talvani A, Rocha MO, Cogan J, et al. Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. Mem Inst Oswaldo Cruz 2004;99(6):645-9
57. Wang Y, Moreira Mda C, Heringer-Walther S, et al. Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. J Card Fail 2010;16(2): 157-63
58. Machado MN, Suzuki FA, Mouco OC, et al. Positive troponin T in a chagasic patient with sustained ventricular tachycardia and no obstructive lesions on cine coronary angiography. Arq Bras Cardiol 2005;84(2):182-4
59. Alarcon-Corredor OM, Carrasco-Guerra H, Ramirez De Fernandez M, Leon W. Serum enzyme pattern and local enzyme gradients in chronic chagasic patients. Acta Cient Venez 2002;53(3):210-17
60. Combs TP, Nagajyothi Mukherjee S, et al. The adipocyte as an important target cell for Trypanosoma cruzi infection. J Biol Chem 2005;280(25):24085-94
61. Rivera MT, De Souza AP, Moreno AH, et al. Progressive Chagas' cardiomyopathy is associated with low selenium levels. Am J Trop Med Hyg 2002;66(6):706-12
62. Adesse D, Lisanti MP, Spray DC, et al. Trypanosoma cruzi infection results in the reduced expression of caveolin-3 in the heart. Cell Cycle 2010;9(8):1639-46
63. Dhiman M, Nakayasu ES, Madaiah YH, et al. Enhanced nitrosative stress during Trypanosoma cruzi infection causes nitrotyrosine modification of host proteins: implications in Chagas' disease. Am J Pathol 2008;173(3):728-40
64. Wen JJ, Vyatkina G, Garg N. Oxidative damage during chagasic cardiomyopathy development: role of mitochondrial oxidant release and inefficient antioxidant defense. Free Radic Biol Med 2004;37(11):1821-33
65. Herrera RN, Diaz E, Perez Aguilar R, et al. Prothrombotic state in early stages of chronic Chagas' disease. Its association with thrombotic risk factors. Arch Cardiol Mex 2005;75 Suppl 3:S3-38-48
66. Melo RC, Fabrino DL, Dias FF, Parreira GG. Lipid bodies: structural markers of inflammatory macrophages in innate immunity. Inflamm Res 2006;55(8): 342-8
67. Ndao M, Spithill TW, Caffrey R, et al. Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling. J Clin Microbiol 2010;48(4):1139-49
68. Ndao M. Biomarker discovery in serum/ plasma using surface enhanced laser desorption ionization time of flight (SELDITOF) mass spectrometry. Methods Mol Biol 2012;818:67-79
69. Pinazo MJ, Tassies D, Munoz J, et al. Hypercoagulability biomarkers in Trypanosoma cruzi -infected patients. Thromb Haemost 2011;106(4):617-23
70. Britto C, Cardoso A, Silveira C, et al. Polymerase chain reaction (PCR) as a laboratory tool for the evaluation of the parasitological cure in Chagas disease after specific treatment. Medicina (B Aires) 1999; 59(Suppl 2):176-8
71. Britto C, Cardoso MA, Vanni CM, et al. Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evaluation. Parasitology 1995;110(3):241-7
72. Britto C, Silveira C, Cardoso MA, et al. Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction. Mem Inst Oswaldo Cruz 2001;96(6):823-6
73. Fernandes CD, Tiecher FM, Balbinot MM, et al. Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem Inst Oswaldo Cruz 2009;104(1):27-32
74. Lana M, Lopes LA, Martins HR, et al. Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment. Mem Inst Oswaldo Cruz 2009;104(8):1139-47
75. Apt W, Arribada A, Zulantay I, et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment. Ann Trop Med Parasitol 2005;99(8):733-41
76. Sanchez G, Coronado X, Zulantay I, et al. Monitoring the efficacy of specific treatment in chronic Chagas disease by polymerase chain reaction and flow cytometry analysis. Parasite 2005;12(4):353-7
77. Zulantay I, Honores P, Solari A, et al. Use of polymerase chain reaction (PCR) and hybridization assays to detect Trypanosoma cruzi in chronic chagasic patients treated with itraconazole or allopurinol. Diagn Microbiol Infect Dis 2004;48(4):253-7
78. Lacunza CDN, Sa'nchez O, Mora MC, et al. Use of the polymerase chain reaction (PCR) for early evaluation etiological treatment in young adults, chronically infected with Trypanosoma cruzi. Rev Patol Trop 2006;35:227-32
79. Murcia L, Carrilero B, Munoz MJ, et al. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country. J Antimicrob Chemother 2010;65(8):1759-64
80. Perez-Ayala A, Perez-Molina JA, Norman F, et al. Chagas disease in Latin American migrants: a Spanish challenge. Clin Microbiol Infect 2011;17(7):1108-13
81. Galvao LM, Chiari E, Macedo AM, et al.R assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. J Clin Microbiol 2003; 41(11):5066-70
82. Sosa-Estani S, Cura E, Velazquez E, et al. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Rev Soc Bras Med Trop 2009;42(5):484-7
83. Aguiar C, Batista AM, Pavan TB, et al. Serological profiles and evaluation of parasitaemia by PCR and blood culture in individuals chronically infected by Trypanosoma cruzi treated with benzonidazole. Trop Med Int Health 2012; 17(3):368-73
84. Machado-De-Assis GF, Silva AR, Do Bem VA, et al. Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests. Clin Vaccine Immunol 2012;19(8): 1283-91
85. Solari A, Ortiz S, Soto A, et al. Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR. J Antimicrob Chemother 2001;48(4):515-19
86. Gomes YM, Lorena VM, Luquetti AO. Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow up studies? Mem Inst Oswaldo Cruz 2009; 104(Suppl 1):115-21
87. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? Jama 1999;282(8):790-5
88. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004;1(2): 189-95
89. Fabbro D, Velazquez E, Bizai ML, et al. Evaluation of the ELISA-F29 test as an early marker of therapeutic efficacy in adults with chronic Chagas disease. Rev Inst Med Trop Sao Paulo 2013;55(3
90. Ashmus RA, Schocker NS, Cordero-Mendoza Y, et al. Potential use of synthetic alpha-galactosyl-containing glycotopes of the parasite Trypanosoma cruzi as diagnostic antigens for Chagas disease. Org Biomol Chem 2013;11(34): 5579-83
91. Nagarkatti R, Fortes De Araujo F, Gupta C, et al. Aptamer Based, Non-PCR Non-Serological, Detection of Chagas Disease Biomarkers in Trypanosoma cruzi Infected Mice. PLoS Negl Trop Dis 2014; 8(1):e2650